Danazol in the treatment of myelodysplastic syndromes

Antônio C. Buzaid, Harinder S. Garewal, Scott M. Lippman, Brian G.M. Durie, Suresh Katakkar, Bernard R. Greenberg
In: European Journal of Haematology · 1987 · vol. 39(4) , pp. 346–348 · doi:10.1111/j.1600-0609.1987.tb00780.x · PMID:3319676 · W2034202205
article OA: closed CC0 ⤵ 15 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Danazol treatment of 20 myelodysplastic syndrome patients resulted in short-lived, clinically insignificant platelet count increases in three patients, with no response observed for anemia or leukopenia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

20 patients with myelodysplastic syndromes (MDS) were treated with danazol, 800 mg daily in 4 divided doses. 18 patients were evaluable for response. 3 patients (17%), whose principal problem was anemia, responded to treatment, but only with an increase in platelet count. Responses were short-lived and lacked clinical significance. No patients with anemia or leukopenia responded to treatment and none of the 7 patients with a platelet count less than 30 x 10(9)/l responded. Danazol appears to have limited clinical utility in the treatment of MDS. However, occasional patients with thrombocytopenia may benefit.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (15)

Source provenance

openalex
last seen: 2026-05-11T06:35:44.859312+00:00
License: CC0 · commercial use OK